Monitoring Disease Progression in GEP-NETs

In gastroenteropancreatic neuroendocrine tumors (GEP-NETs), assessment of tumor size alone is a suboptimal means of tracking disease progression. This is because GEP-NETs tend to grow slowly, and treatments tend to stabilize, rather than shrink the tumor.^1-3 Therefore, it is important to monitor progression criteria for GEP-NETs such as morphological progression,^1,4 symptomatic progression,^1,5,6 and progression on nuclear medicine imaging.^1,7 See recommended monitoring frequency and additional details in the infographic below.

References: 1. Merino-Casabiel X, et al. Clin Transl Oncol. 2018;20:1522–1528; 2. Yao J, et al. N Engl J Med. 2011;364:514–523; 3. Raymond E, et al. N Engl J Med. 2011;364:501–513; 4. Eisenhauer EA, et al. Eur J Cancer. 2009;45:228–247; 5. de Mestier L, et al. Endocr Rel Cancer. 2014;21:R105–R120; 6. Yao J, et al. J Clin Oncol. 2010;28:69–76; 7. Virgolini I, et al. Eur J Nucl Med Mol Imaging. 2010;37:2004–2010.